[99mTc]-HM-PAO SPECT in Parkinson's Disease

Thirty-six patients affected by Parkinson's disease were studied using single photon emission computed tomography (SPECT) and [99mTc]–HM-PAO as a tracer. The scanning procedure was performed 16–24 h after discontinuation of specific therapy. Tracer activity ratios were determined in 10 pairs of cerebellar, cortical, and subcortical regions. Data were compared with those of 10 age-matched controls. Most of the regions examined did not show any relevant change between parkinsonian and control subjects. Notably, mean activity in striatal regions were similar in the two groups. Increased activity in caudate–putamen was found in patients who were on chronic DOPA therapy. Side-to-side asymmetries in the basal ganglia increased with the severity of the disease. Significant reductions of tracer uptake, from control values, were observed bilaterally in the parietal cortex. These deficits were more pronounced in patients with mental deterioration and in subjects who had been chronically treated with anticholinergic drugs. Parietal perfusion deficits in parkinsonian patients resemble those described in Alzheimer's dementia. These findings suggest that the heterogeneous alterations of regional cerebral blood flow (rCBF) in parkinsonian patients reflect the multifactorial pathophysiology of the disease.

[1]  F. Boiler Mental status of patients with parkinson disease , 1980 .

[2]  Y. Agid,et al.  CCK-8-immunoreactivity distribution in human brain: selective decrease in the substantia nigra from parkinsonian patients , 1982, Brain Research.

[3]  K. Jellinger,et al.  Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. , 1973, Journal of the neurological sciences.

[4]  P. Jarritt,et al.  A 99Tcm-labelled radiotracer for the investigation of cerebral vascular disease , 1985, Nuclear medicine communications.

[5]  O. Hornykiewicz,et al.  Distribution of high affinity sodium-independent [3H]gamma-aminobutyric acid ([3H]GABA) binding in the human brain: Alterations in Parkinson's disease , 1977, Brain Research.

[6]  G. Deutsch,et al.  Cerebral blood flow in severity‐matched Alzheirner and multi‐infarct patients , 1987, Neurology.

[7]  E. London,et al.  Effects of oxotremorine on local glucose utilization in the rat cerebral cortex , 1982, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[8]  J. Haxby,et al.  Positron emission tomography in Alzheimer's disease , 1986, Neurology.

[9]  S. Rapoport,et al.  Stimulatory Effect of the D2 Antagonist Sulpiride on Glucose Utilization in Dopaminergic Regions of Rat Brain , 1987, Journal of neurochemistry.

[10]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[11]  T Jones,et al.  Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. , 1986, Journal of neurology, neurosurgery, and psychiatry.

[12]  Marcus E. Raichle,et al.  Regional blood flow in herniparkinsonism , 1985, Neurology.

[13]  M. Albert,et al.  Muscarinic acetylcholine receptors in Alzheimer's disease. In vivo imaging with iodine 123-labeled 3-quinuclidinyl-4-iodobenzilate and emission tomography. , 1985, JAMA.

[14]  P. Mcgeer,et al.  Aging and extrapyramidal function. , 1977, Archives of neurology.

[15]  T Jones,et al.  Alterations of regional cerebral blood flow and oxygen metabolism in Parkinson's disease , 1985, Neurology.

[16]  A. Hakim,et al.  Dementia in Parkinson disease , 1979, Neurology.

[17]  O. Hornykiewicz Dopamine (3-hydroxytyramine) and brain function. , 1966, Pharmacological reviews.

[18]  M. Kupersmith,et al.  Dementia in Parkinson disease , 1979, Annals of neurology.

[19]  W. Jagust,et al.  The diagnosis of dementia with single photon emission computed tomography. , 1987, Archives of neurology.

[20]  U. Rinne,et al.  Brain catecholamines and their metabolites in Parkinsonian patients. Treatment with levodopa alone or combined with a decarboxylase inhibitor. , 1973, Archives of neurology.

[21]  L. Henriksen,et al.  Regional cerebral blood flow in hemiparkinsonian patients. Emission computerized tomography of inhaled 133Xenon before and after levodopa , 1985, Acta neurologica Scandinavica.

[22]  E. London,et al.  Glucose utilization in the Papez circuit: Effects of oxotremorine and scopolamine , 1984, Brain Research.

[23]  P F Sharp,et al.  Technetium-99m HM-PAO stereoisomers as potential agents for imaging regional cerebral blood flow: human volunteer studies. , 1986, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[24]  M. Hoehn,et al.  Parkinsonism , 1967, Neurology.

[25]  A. Hirano,et al.  AN ATLAS OF THE HUMAN BRAIN FOR COMPUTERIZED TOMOGRAPHY. , 1978 .

[26]  Y. Agid,et al.  Muscarinic binding and choline acetyltransferase activity in Parkinsonian subjects with reference to dementia , 1982, Brain Research.

[27]  R Harrop,et al.  Cerebral Glucose Metabolism in Parkinson’s Disease , 1984, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[28]  N. Foster,et al.  Alzheimer's disease , 1983, Neurology.

[29]  Y Agid,et al.  Is the mesocortical dopaminergic system involved in Parkinson disease? , 1980, Neurology.

[30]  Stanley I. Rapoport,et al.  Arecoline-induced elevations of regional cerebral metabolism in the conscious rat , 1985, Brain Research.

[31]  J. Coyle,et al.  Jo U Rnal of Cerebral Blood Flow and Metabolism Decreased Cortical Glucose Utilization after Ibotenate Lesion of the Rat Ventromedial Globus Pallidus , 2022 .

[32]  R A Holmes,et al.  Technetium-99 m d , l-HM-PAO : A New Rathopharmaceutical for SPECT Imaging of Regional CerebralBlood Perfusion , 2006 .

[33]  D. Nowotnik,et al.  Technetium-99m-d, 1-HM-PAO: a new radiopharmaceutical for imaging regional brain perfusion using SPECT--a comparison with iodine-123 HIPDM. , 1986, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[34]  M E Raichle,et al.  Regional blood flow in hemiparkinsonism. , 1985, Neurology.

[35]  T. Jones,et al.  Regional impairment of cerebral oxidative metabolism in Parkinson's disease. , 1979, Journal of neurology, neurosurgery, and psychiatry.

[36]  S. Rapoport,et al.  Time-course and regional distribution of the metabolic effects of bromocriptine in the rat brain , 1985, Brain Research.

[37]  T T Soncrant,et al.  Haloperidol and Cerebral Metabolism in the Conscious Rat: Relation to Pharmacokinetics , 1984, Journal of neurochemistry.

[38]  P. Seeman,et al.  Dopamine D2 receptor density in parkinsonian brain is constant for duration of disease, age, and duration of L-dopa therapy. , 1987, Advances in neurology.

[39]  U. Roessmann,et al.  Parkinson disease, dementia, and alzheimer disease: Clinicopathological correlations , 1980, Annals of neurology.

[40]  D L Price,et al.  Basal forebrain neurons in the dementia of Parkinson disease , 1983, Annals of neurology.

[41]  D E Kuhl,et al.  Patterns of local cerebral glucose utilization determined in Parkinson's disease by the [18F]fluorodeoxyglucose method , 1984, Annals of neurology.

[42]  E. Melamed,et al.  Cerebral blood flow and cognitive impairment in Parkinson's disease , 1985, Neurology.

[43]  Olaf B. Paulson,et al.  The Retention of [99mTc]-d,l-HM-PAO in the Human Brain after Intracarotid Bolus Injection: A Kinetic Analysis , 1988, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.